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Infectious  pancreatic  necrosis  virus  (IPNV)  is  one  of  the  major  viral  pathogens  causing  disease  in  farmed
Atlantic  salmon  worldwide.  In the  present  work  we  show  that several  of the  IPN proteins  have powerful
antagonistic  properties  against  type  I IFN  induction  in  Atlantic  salmon.  Each of  the  ﬁve  IPNV  genes  cloned
into  an expression  vector  were  tested  for the  ability  to  inﬂuence  activation  of the  Atlantic  salmon  IFNa1
promoter  by  the  interferon  promoter  inducing  protein  one  (IPS-1)  or interferon  regulatory  factors  (IRF).
This showed  that  preVP2,  VP3 and  VP5  inhibited  activation  of  both  promoters,  while  VP4  only  antagonized
activation  of  the IFNa1  promoter.  The  viral  protease  VP4  was  the  most  potent  inhibitor  of  IFN  induction,
apparently  targeting  the  IRF1  and  IRF3  branch  of  the signaling  cascade.  VP4  antagonism  is independent
of  its protease  activity  since  the  catalytically  dead mutant  VP4K674A  inhibited  activation  of the IFNa1
promoter  to  a  similar  extent  as  wild  type  VP4.  In  contrast  to the other  IPNV  proteins,  the  RNA-dependentPS-1
RF1
RF3
RNA  polymerase  VP1  activated  the IFNa1  promoter.  The  ability  to activate  the  IFN  response  was  disrupted
in the  mutant  VP1S163A,  which  has  lost  the  ability  to produce  dsRNA.  VP1 also  exhibited  synergistic
effects with  IRF1  and  IRF3  in  inducing  an  IFNa1-dependent  antiviral  state  in cells.  Taken  together  these
results  suggest  that  IPNV  has  developed  multiple  IFN  antagonistic  properties  to  prevent  IFN-induction
by  VP1  and  its dsRNA  genome.
©  2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
Infectious pancreatic necrosis virus (IPNV) causes disease and
ortality in hatchery-reared salmonid fry and in Atlantic salmon
ostsmolts after transfer to the sea (Hill and Way, 1995; Jarp
t al., 1995; Smail et al., 1992). Elucidation of how IPNV interacts
ith the innate immune system of Atlantic salmon is impor-
ant to understand its pathogenic properties. IPNV belongs to
he genus Aquabirnavirus of the Birnaviridae family. The genome
onsists of two double-stranded (ds) RNA segments, packed in a
on-enveloped single-shelled icosahedrical capsid (Coulibaly et al.,
005; Dobos, 1976; Pous et al., 2005). Segment B encodes VP1,
hich is a 94 kDa RNA dependent RNA polymerase (RdRp) found
oth in a free and a genome-linked form in the virion (Dobos,
995). Segment A contains a single large open reading frame (ORF)
hat encodes a polyprotein, which is co-translationally cleaved by
he non-structural protease VP4 to generate the mature structural
roteins VP2 and VP3 (Duncan et al., 1987). VP2 is the outer cap-
id protein while VP3 is found in the inner surface of the viral
∗ Corresponding author. Tel.: +47 77644487; fax: +47 77646020.
E-mail address: borre.robertsen@uit.no (B. Robertsen).
ttp://dx.doi.org/10.1016/j.virusres.2014.11.018
168-1702/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
capsid. VP3 has recently been shown to interact with VP1 and with
double-stranded RNA (Pedersen et al., 2007). In addition, segment
A contains a small overlapping ORF encoding VP5, which is a non-
structural protein with undeﬁned properties, proposed to have an
anti-apoptotic function and to be of importance for virulence (Santi
et al., 2005). The size of VP5 varies depending on the isolate, from
15 kDa to 3.3 kDa, but some isolates lack the VP5 reading-frame
altogether (Heppell et al., 1995; Skjesol et al., 2011).
To establish a systemic infection, viruses have developed a wide
range of mechanisms to evade and subvert the type I interferon
(IFN) system, which plays a crucial role in the innate immunity
against viruses of vertebrates (van den Broek et al., 1995). Type
I IFNs are induced upon recognition of viral RNA by the RNA
helicases RIG-I and MDA5 in the cytoplasm, and by the toll-like
receptors TLR3 and TLR7, which are embedded in the membrane of
endosomes (Arpaia and Barton, 2011; Takeuchi and Akira, 2007).
Upon release, IFNs induce a range of antiviral proteins both in
non-infected and infected cells preventing further virus infection.
Among the antiviral proteins are Mx,  ISG15, viperin and PKR (Chin
and Cresswell, 2001; Liu et al., 2011; Samuel, 2001). Targeting
initiation of transcription of IFN and IFN-induced genes are fre-
quently used strategies for viruses to establish an infection in the
host (Randall and Goodbourn, 2008). IPNV VP4 and VP5 have been
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table 1
Plasmid constructs.
Plasmid Reference
pDESTmycVPl Skjesol et al. (2009)
pDESTmycpreVP2 Skjesol et al. (2009)
pDESTmycVP3 Skjesol et al. (2009)
pDESTmycVP4 Skjesol et al. (2009)
pDESTmycVP5 Skjesol et al. (2009)
pIPS-1 Lauksund et al. (2009)
pIRFIHA Bergan et al. (2010)
pIRF3HA Bergan et al. (2010)
pA1(-202) Bergan et al. (2006)
pDESTmycVP1S163A This study
pDESTmycVP4K674A This study
pVP1ﬂag This study
pVP4ﬂag This study
pVP1S163Aﬂag This study
pVP4K674Aﬂag This study
pGL3basic Promega corporation
pGL74 Promega corporation
2.5. Site-directed mutagenesis14 S. Lauksund et al. / Virus
hown to inhibit IFN-induced activation of the Mx  promoter, but
he effect of IPNV proteins on induction of type I IFN is unknown
Skjesol et al., 2009).
Atlantic salmon possesses at least four type I IFN subtypes, IFNa,
FNb, IFNc and IFNd, which show large differences in sequence
nd expression properties (Svingerud et al., 2012). IFNa1, IFNb and
FNc all show potent antiviral activity against IPNV and they induce
x protein, which inhibits IPNV replication (Rokenes et al., 2007;
vingerud et al., 2012). In this work we chose to study the inﬂuence
f IPNV proteins on activation of the Atlantic salmon IFNa1 pro-
oter since IFNa1 is induced in most cells upon stimulation with
sRNA, while IFNb and IFNc are mainly induced in lymphoid organs
Sun et al., 2009; Svingerud et al., 2012). Salmon IFNa1 shows
xpression properties strikingly similar to mammalian IFN, which
s induced through the RIG-I/MDA5 and TLR3 pathways (Bergan
t al., 2006; Sun et al., 2009; Svingerud et al., 2012). Similar to
he human IFN promoter, the salmon IFNa1 promoter has one
FB-binding site and two IRF binding sites (Bergan et al., 2006).
Teleost ﬁsh possess all key components of the RIG-I/MDA5
ignaling pathway, including RIG-I, MDA5, IPS-1, MITA, TBK1 and
RFs (Bergan et al., 2010; Biacchesi et al., 2009; Chang et al., 2011;
eng et al., 2011; Holland et al., 2008; Lauksund et al., 2009; Ohtani
t al., 2011, 2012; Simora et al., 2010; Su et al., 2010; Sun et al.,
011; Zou et al., 2009). In mammals, RIG-I and MDA5 interact
ith the adaptor protein IPS-1 upon binding viral RNA (Berke and
odis, 2012; Jiang et al., 2011), which activates the transcription
actors IRF-3, IRF-7 and NFB, resulting in start of IFN transcrip-
ion (Randall and Goodbourn, 2008). In Atlantic salmon, IPS-1, IRF1
nd IRF3 are strong inducers of the IFNa1 promoter (Bergan et al.,
010; Lauksund et al., 2009).
In a previous work, we noticed that IPNV infection failed to
nduce the Atlantic salmon IFNa1 promoter (Bergan et al., 2006).
o elucidate the reason why the virus does not induce a success-
ul IFN response, we here investigated the effect of the individual
PNV proteins on IFNa1 induction. The present work demonstrates
hat IPNV has developed multiple mechanisms to inhibit induction
f IFNa1 transcription. Surprisingly, however, we  found that VP1
trongly activated IFNa1 transcription, which may  in part explain
hy the virus needs potent IFN-antagonistic properties.
. Materials and methods
.1. Cells and viruses
Atlantic salmon TO cells (Wergeland and Jakobsen, 2001) were
btained from Dr. Heidrunn Wergeland (University of Bergen,
ergen, Norway). TO cells were cultivated at 20 ◦C in L-15 medium
Gibco, Life technologies) supplemented with 1% non-essential
mino acids, 100 g/ml streptomycin, 100 units/ml penicillin (Life
echnologies) and 8% fetal bovine serum (FBS) superior (Biochrom
G). IPNV serotype Sp N1 (Christie et al., 1988) was propagated in
HSE cells and viral titer was determined to be 1 × 107 in CHSE cells
ased on the TCID50 method (42). The virus was stored at −80 ◦C
ntil use (Reed and Muench, 1938).
.2. Infection of TO cells by IPNV
TO cells were seeded in 24-well plates and 100% conﬂuent cells
ere infected with 10 MOI  of IPNV or left untreated (control). The
ells (treated in triplicates) were harvested after 6, 12, 24 and 48 h.
.3. Neon transfections and luciferase assaysTO cells were split 2:3 the day before transfection. The cells were
ransfected at 80% conﬂuence using the 10 l Neon transfection
ystem (Life technologies) with buffer R and at a pulse voltage ofpcDNA3.1 Invitrogen – Life technologies
pcDNA3.3 Invitrogen – Life technologies
110, pulse width 30 ms,  2 pulses. For each transfection 450,000 cells
were used. For each well a total of 500 ng luciferase vector and test
vectors were used, and 50 ng of the pGL74 Renilla luciferase vector
was included as a transfection control. The expression vectors used
are shown in Table 1. After transfection the cells were seeded in 24-
well plates with L-15 medium with 12% FBS, without antibiotics,
and incubated at 20 ◦C. Cells were harvested in 50 l passive lysis
buffer and 10 l of the sample was measured according to the dual-
luciferase reporter assay system protocol (Promega). Results are
shown as relative light units (RLU) of test reporter (ﬁreﬂy luciferase)
over control reporter (Renilla luciferase).
2.4. Antiviral assay and IFN neutralization
TO cells were transfected in 10 l Neon transfection reactions
as described in the previous section, resuspended in 400 l growth
media without antibiotics and transferred to 4 wells in a 96-well
plate containing 100 l growth media without antibiotics. Con-
trol cells were treated the same way without plasmid present. The
cells were incubated at 20 ◦C for 72 h prior to infection. Cells were
infected with IPNV at a multiplicity of infection (MOI) of 0.1 in L-
15 without supplements for 1 h before changing to growth media
with 2% FBS. The supernatants from the transfected cells were har-
vested and stored at −80 ◦C until use in antiviral and antibody
neutralization assay. For the IFN neutralization assay, TO cells were
seeded in 96 well plates at a density of 2 × 104 cells per well. The
supernatant was  divided in two, and one part was  pre-incubated
with IFNa1 antibody at a 1:100 dilution for 1 h at 37 ◦C. Untreated
supernatant was also incubated for 1 h at 37 ◦C. The cells were incu-
bated with 100 l of either untreated or neutralized supernatant
for 24 h, and subsequently infected with IPNV at a MOI  of 0.1 as
previously described. When complete cytopathogenic effect (CPE)
was observed in control cells four days after infection, cell survival
was determined by crystal violet staining as described in (Lauksund
et al., 2009). Viral titration was determined in TO cells seeded in 96
well plates at a density of 2 × 104 cells per well. Calculation of viral
titer was determined by the TCID50 method (Reed and Muench,
1938).Mutations were introduced to the VP1 and VP4 genes by
site-directed mutagenesis using the GeneArt® Site-Directed Muta-
genesis System from Invitrogen and the following primers:
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VP1S163Afwd: 5′-CTGCAATACGGGTCCGGCGCCTACTCAGGACAA-
CTC-3′ and VP1S163Arev: 5′-GAGTTGTCCTGAGTAGGCGCCGGA-
CCCGTATTGCAG-3′;
VP4K674Afwd: 5′-GCGGTGTAGACATCGCAGCCATCGCAGCCCAT-
GAAC-3′ and VP4K674Arev: 5′-GTTCATGGGCTGCGATGGCTGCGA-
TGTCTACACCGC-3′.
Mutagenesis was performed according to the speciﬁcations in
he kit.
.6. Subcloning
Plasmids containing the VP1, VP1S163A, VP4 and VP4K674A
ene sequences were used as templates and new constructs with
lag tag were ampliﬁed by PCR with primers which included a Flag
ag sequence (DYKDDDDK) in the N-terminal of each ORF segment.
hese PCR products were cloned into a pcDNA3.3 plasmid (Invitro-
en). The following primer sequences were used:
VP1fwd, 5′-CACCATGGACTACAAAGACGATGACGACAAGATGTCG-
GACATCTTCAATTC-3′ and VP1rev, 5′-TCAGTTTCTTCTCTGCTTCTC-
CCGACG-3′;
VP4fwd, 5′-CACCATGGACTACAAAGACGATGACGACAAGAGCGGA-
GGGCCCGACGGAAA-3′ and VP4rev, 5′-TCATGCATTTGATGCCATC-
AGCTCTCCCAGGTACT-3′.
.7. Relative quantitative real time PCR (qPCR) analysis
RNA was isolated from neon-transfected or infected TO-cells by
sing an RNeasy Mini Kit (Qiagen, Santa Clarita, CA). RNA integrity
as veriﬁed by 1% agar gel electrophoresis, Quantity of RNA
as assessed with the NanoDrop® ND-1000 spectrophotometer
NanoDrop Technologies, Wilmington, DE, USA). Criterion to
nclude RNA samples was 260/280 nm absorbance ratio of 1.9–2.2.
.2 g of DNase-treated total RNA was reverse-transcribed to
DNA with oligo(dT) primers in a 20 l reaction (QuantiTect®
everse Transcription Kit (QIAGEN)). For PCR primer efﬁciency, a
en-fold dilution series with eight measuring points from a random
ool of cDNA was used. The efﬁciencies were calculated by the
ormula: efﬁciency (%) = (10(−1/slope) − 1)*100. PCR primer efﬁcien-
ies (between 2.04 and 2.22) were close to 100% allowing use of
he 2−CT method for calculation of relative gene expression
43). The qPCR assays were carried out with the ABI PRISM 7700
equence Detection System using 2× Fast SYBR® Green Master
ix  (Applied Biosystems) in a 15 l reaction volume, with 6 l
:10 diluted cDNA, and primer concentrations of 0.50 M.  PCRs
ere run in triplicates in 96-well optical plates system under the
ollowing conditions: 95 ◦C for 5 min  (pre-incubation), 95 ◦C for
 s, 60 ◦C for 15 s, 72 ◦C for 15 s (45 cycles) and continuous increase
rom 65 ◦C to 97 ◦C with standard ramp rate (melting curve). 18S
sed as a reference gene showed stable expression in control
nd test samples according to the BestKeeper software (Pfafﬂ
t al., 2002). The following primers were used for the relative
uantiﬁcation: IFNa, 5′-TGCAGTATGCAGAGCGTGTG-3′ and 5′-
CTCCTCCCATCTGGTCCAG-3′; IFNb, 5′-TGCATTGGAGGCTATGCGA-
AT-3′ and 5′-TTCCCAAACACCACCTACGACA-3′; IFNc, 5′-ATGTAT-
ATGGGCAGTGTGG-3′ and 5′-CCAGGCGCAGTAACTGAAAT-3′;
8S, 5′-TTGCCGCTAGAGGTGAAATT-3′ and 5′-GCAAATGCTTTCGC-
TTCG-3′; EF1, 5′-TGCCCCTCCAGGATGTCTAC-3′ and 5′-CAC-
GCCCACAGGTACTG-3′; VP2, 5′-GCCAAGATGACCCAGTCCAT-3′
nd 5′-TGACAGCTTGACCCTGGTGAT-3′..8. Western blotting
TO cells were split 2:3 the day before transfection. The cells were
ransfected at 80% conﬂuence using the 10 l Neon transfectionrch 196 (2015) 113–121 115
system (Life technologies) with buffer R and at a pulse voltage of
1200, pulse width 20 ms,  2 pulses. 450,000 cells were used for
each transfection. For each well a total of 350 ng plasmid were
used. After transfection the cells were seeded in 48-well plates in
triplicates with MEM  growth medium containing 12% FBS without
antibiotics, and incubated with CO2 at 20 ◦C. Cells were harvested
48 h post transfection in 40 l 2× SDS buffer. 15–20 l of the sam-
ples were loaded in each well of a precast 4–12% gradient NuPAGE
Novex Bis-Tris gel and subjected to SDS–polyacrylamide gel elec-
trophoresis (SDS–PAGE) with 1× MOPS (Invitrogen) for 45 min  at
200 V and 120 mA.  The markers MagicMarkTM XP (Invitrogen) and
SeeBlue Plus2 Prestained (Invitrogen) were simultaneously loaded
for molecular weight estimations. Western blotting of the sepa-
rated proteins to a polyvinylidene diﬂuoride (PVDF) membrane
(Millipore) was  performed using the Invitrogen NuPAGE system
according to the manufacturer’s instructions. An anti-Flag antibody
(1:3000 dilution) (Sigma) for detection of Flag-tagged proteins
were used and goat anti-mouse-HRP antibody (1:5000) (Santa Cruz
Biotechnology) as a secondary antibody.
2.9. Statistical analyses
Two-sided unpaired Student t test was  used to calculate statis-
tics, where p ≤ 0.05 was  considered to indicate a statistically
signiﬁcant difference.
3. Results
3.1. IPNV infection does not induce IFNa transcription in cell
culture
To study the effect of IPNV infection on the IFN response, TO-
cells were infected with IPNV at an MOI  of 10, and expression of
IFN transcripts and VP2 transcripts were measured after 6–48 h
(Fig. 1). The cells showed beginning CPE at 48 h and strong CPE at
72 h after infection. The IFNa expression showed relatively small
changes in infected cells compared to uninfected control cells,
where only a minor increase in IFNa transcripts was observed at 6 h
(1.5 times) (Fig. 1A). As expected, the expression of the viral protein
VP2 showed a strong increase throughout the 48 h infection period
(Fig. 1B). IPNV does thus not induce IFNa during infection of TO
cells, which supports that the virus may  express IFN antagonizing
proteins.
3.2. IPNV preVP2, VP3, VP4 and VP5 proteins inhibit IFNa1
promoter activation while VP1 activates the IFNa1 promoter
To measure the effect of IPNV proteins on IFNa1 promoter
activation, we used a previously described reporter gene con-
struct where the Atlantic salmon IFNa1 minimal promoter region
controls expression of a luciferase gene (Bergan et al., 2006).
As activator of the IFNa1 promoter, we  used Atlantic salmon
IPS-1, which is known to activate the IFNa1 promoter upon
overexpression (Lauksund et al., 2009). IPS-1 is a key adapter
protein in the RIG-I/MDA5 signaling pathway, which controls
type I IFN expression in most cells. TO-cells were co-transfected
with the reporter plasmid and a plasmid containing one of the
IPNV genes and a plasmid expressing IPS-1. Luciferase activity
in the cells was  measured at 48 h after transfection. The results
showed that the viral proteins preVP2, VP3, VP4 and VP5 inhib-
ited IPS-1 mediated activation of the IFNa1 promoter (Fig. 2A). The
strongest inhibitory effect was observed with VP4, which virtu-
ally abolished promoter activation. In contrast, VP1 surprisingly
increased activation of the IFNa1 promoter when co-transfected
with IPS-1. To ﬁnd out if VP1 could activate the IFNa1 pro-
moter by itself, individual VP constructs were co-transfected
116 S. Lauksund et al. / Virus Research 196 (2015) 113–121
F antita
( ed rel
i
w
l
d
a
c
I
n
m
t
v
F
p
g
t
p
i
o
I
mig. 1. Expression of IFNa and VP2 in IPNV infected TO cells measured by qPCR. Qu
MOI  10). Gene expression was normalized against EF1. Expression was determin
nfection time point for VP2 (mean Ct = 31). Values are mean ± SD (N = 3).
ith IFNa1 promoter construct into TO cells and assayed for
uciferase expression. As shown in Fig. 2B, VP1 expression alone
id indeed activate the IFNa1 promoter while preVP2-VP5 gave
 reduction in promoter activity compared with the transfection
ontrol.
Since activation of type I IFN transcription through the RIG-
/MDA5 pathway ultimately results in activation of IRFs, we
ext studied the effect of IPNV proteins on IRF1 and IRF3
ediated activation of the IFNa1 promoter. Overexpression of
hese IRFs has previously been shown to result in strong acti-
ation of the IFNa1 promoter (Bergan et al., 2010). In these
ig. 2. Effect of IPNV proteins on activation of the Atlantic salmon IFNa1 promoter. In
lasmid containing the IFNa1 promoter fused to a luciferase gene, a plasmid containing 
ene  (VP1-VP5), and a control plasmid or a plasmid containing a gene encoding a sign
ransfection and analyzed for promoter activation by measuring luciferase activity. Resu
roteins on IPS-1 mediated activation of the promoter. Signiﬁcant differences (p < 0.05)
ndividual IPNV proteins on promoter activation. Signiﬁcant difference (p < 0.05) from ve
n  IRF1 mediated activation of the promoter. Signiﬁcant differences (p < 0.05) from vecto
RF3  mediated activation of the promoter. Signiﬁcant differences (p < 0.05) from vector co
ediated activation of the promoter. Signiﬁcant differences (p < 0.05) from vector controtive PCR showing expression of IFNa (A) and VP2 (B) in TO cells infected with IPNV
ative to transcript levels in uninfected TO cells (=1) for IFNa, and relative to the 6 h
experiments VP constructs were co-transfected with the pro-
moter construct and an expression plasmid encoding either
IRF1 or IRF3. The results showed that preVP2, VP3, and VP4
strongly inhibited both IRF1 and IRF3 mediated activation of the
IFNa1 promoter. VP5 had inhibitory effect against IRF1 medi-
ated activation of the promoter, but did not cause signiﬁcant
inhibition of IRF3 mediated activation of the IFNa1 promoter
(Fig. 2C and D).
Taken together, the data showed that preVP2, VP3, VP4 and
VP5 were all able to inhibit IPS-1, IRF1 and IRF3 mediated acti-
vation of the IFNa1 promoter. Since we  observed IFNa1-promoter
 all experiments TO-cells were co-transfected with four expression constructs; a
the Renilla luciferase gene as a transfection control, a plasmid containing an IPNV
aling protein in the IFNa1 induction pathway. Samples were harvested 48 h after
lts are presented as mean relative light units (RLU) ± SD (N = 3). (A) Effect of IPNV
 from vector control and IPS-1 indicated by * and †, respectively. (B) Effect of the
ctor control and IPS-1 indicated by * and †, respectively. (C) Effect of IPNV proteins
r control and IRF-1 indicated by * and †,  respectively. (D) Effect of IPNV proteins on
ntrol and IRF-3 indicated by * and †,  respectively. (E) Effect of IPNV proteins on VP1
l and VP1 indicated by * and †, respectively.
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Fig. 3. Co-stimulatory effects of VP1 and IRFs on activation of the Atlantic salmon IFNa1 promoter. TO-cells were co-transfected with a plasmid containing the minimal IFNa1
promoter fused to a luciferase gene along with an expression construct for Renilla luciferase as a transfection control. In addition, expression constructs for IRF1 or IRF3,
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gave signiﬁcant protection of cells. The antiviral activity of these
supernatants was  completely blocked by pre-treatment with IFNa1
antibody.
Fig. 4. IFNa expression in TO cells in response to overexpression of VP1 in com-
bination with IRF1 or IRF3. Cells were transfected with expression constructs for
VP1,  IRF1 and IRF3 in combination with plasmid control or VP1 in combination with
IRF1  or IRF3. Cells transfected with IPS-1 or preVP2 were used as positive and neg-
ative control. RNA was extracted after 24 h and IFNa expression was determined
by  qPCR relative to transcript levels in plasmid control transfected cells (=1). Gene
expression was  normalized against 18S rRNA. Values are mean ± SD (N = 3). Aster-P1,  and VP1 in combination with IRF1 or IRF3 were included. Results are presente
P1  and IRF1 and vector control. IRF1 + VP1 is signiﬁcantly different from VP1 and IR
RF3  + VP1 is signiﬁcantly different from VP1 and IRF3 (p < 0.05). All groups are diffe
ctivating properties of VP1, we also wanted to examine if VP2-
P5 had inhibitory effect against this activation. Co-transfection
f TO-cells with IFNa1 promoter construct, VP1 and each of the
ther IPNV genes was performed. The results showed that indeed,
P2–VP5 were also able to inhibit VP1 mediated activation of the
FNa1 promoter (Fig. 2E).
.3. Synergistic effects of VP1 and IRFs on induction of IFNa1
VP1 and IRF1 or VP1 and IRF3 showed strong synergistic effects
n activation of the IFNa1 promoter. Transfecting TO cells with
 combination of IRF1 and VP1 plasmids increased the activa-
ion capacity of VP1 12 times, while combining IRF3 with VP1
ncreased the activation capacity of VP1 by 10.5 times (Fig. 3A and
).
Since overexpression of VP1 activated the IFNa1 promoter, we
anted to study whether VP1 was able to induce transcription of
FN either alone or in combination with IRF1 and IRF3. Accordingly,
O-cells were transfected with plasmids containing VP1 alone or
P1 together with plasmids containing IRF1 or IRF3. Expression
f IFNa in response to IPS-1 plasmid was used as a positive con-
rol and preVP2 was included as a negative control. After 24 h the
ells were harvested, and analyzed for IFNa, IFNb and IFNc trans-
ripts. Transfection with IPS-1 resulted in a 6-fold up-regulation
f IFNa transcripts compared with the control (p < 0.001) (Fig. 4).
p-regulation of IFNa was hardly detectable after transfection with
P1, IRF1 or IRF3 alone whereas the combination of VP1 with either
RF1 or IRF3 showed a 6–8 times up-regulation of IFNa transcript
evels. The preVP2 plasmid showed no signiﬁcant up-regulation of
FNa1 transcripts (p = 0.8). None of the cell groups showed IFNb
ranscripts or up-regulation of IFNc transcripts (data not shown).
.4. Antiviral effect induced by VP1 and IRF1/IRF3 is due to IFNa
Since VP1 together with IRF1/IRF3 activated IFNa transcription,
e wanted to test their ability to induce antiviral activity in TO
ells. The cells were transfected with plasmids expressing VP1,
RF1, IRF3 alone or VP1 in combination with the IRFs, or transfected
ith plasmid without insert for infected and uninfected controls.
fter 72 h, the cell supernatants were harvested for antiviral
ssay of IFN while the cells were infected with IPNV for direct
easurement of antiviral activity on the transfected cells. When
he infected control cells had reached full CPE, the supernatantsean relative light units (RLU) ± SD (N = 3). (A) Effects of IRF1, VP1, a combination of
 < 0.05). (B) Effects of IRF3, VP1, a combination of VP1 and IRF3 and a vector control.
rom vector control in A and B (p < 0.05).
were harvested for viral titration and the remaining cell layer was
stained with crystal violet for measurement of cell survival. The
assay showed signiﬁcant increased cell survival for all plasmid
transfections, but cells transfected with combination of VP1 and
IRF1/IRF3 plasmids showed highest survival (Fig. 5A). This pattern
of antiviral activity was  also observed measured as reduction in
virus titers as shown by the TCID50 calculations shown under the
corresponding bars of OD550 measurements (Fig. 5A).
We next studied if IFN was secreted by cells transfected with the
different plasmid combinations. For this purpose the supernatant
from the transfected cells was added to new TO cells in the pres-
ence or absence of IFNa1 antibody. The cells were incubated for
24 h for induction of antiviral proteins and infected with IPNV. Cell
survival was  measured by crystal violet staining when the infected
control cells had reached full CPE. As shown in Fig. 5B, only super-
natants from cells transfected with combinations of VP1 and IRFsisks denote signiﬁcant differences from vector control (p < 0.05). Cells transfected
with VP1 + IRF1 were signiﬁcantly different from cells transfected with IRF1 + vector
control and from VP1 + vector control (p < 0.005). Cells transfected with VP1 + IRF3
were signiﬁcantly different from cells transfected with IRF3 + vector control and
from VP1 + vector control (p < 0.005).
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Fig. 5. Antiviral activity of VP1, IRF1 and IRF3 against IPNV. (A) TO-cells were trans-
fected with expression constructs for VP1, IRF1, IRF3 alone or VP1 in combination
with IRF1 or IRF3, or empty vector for control samples. Three days after transfection,
supernatants from the transfected cells were harvested and kept for use in the IFN
neutralization assay shown in (B) while the cells were infected with IPNV (MOI 0.1).
When full CPE was  observed after 4 days, the supernatants were harvested for viral
titration, and the surviving cell layer was stained with crystal violet. Cell survival
was  determined by measuring the absorbance at 550 nm.  Viral titers in medium
supernatants from the different treatment groups were determined by the TCID50
method. All groups are different from infected control (p < 0.05). (B) Measurement of
IFN activity in cell supernatants described in (A) in the presence or absence of neu-
tralizing antibody against IFNa1. TO-cells were treated with supernatants for 24 h
and then infected with IPNV as described for (A). At full CPE, cell survival was deter-
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Fig. 6. Effect of the VP1 mutant S163A on activation of the IFNa1 promoter. TO-
cells were co-transfected with a plasmid containing the minimal IFNa1 promoter
fused to a luciferase gene along with an expression construct for Renilla luciferase
as a transfection control. In addition expression constructs for VP1, the mutant
type I IFN (Robertsen et al., 2003; Svingerud et al., 2012). The virusined by staining cells with crystal violet and measuring absorbance at 550 nm.
sterisks denote signiﬁcant differences from infected vector control (p < 0.05).
.5. The ability of VP1 to activate the IFNa1 promoter is
ependent on an intact serine in position 163
VP1 is the IPNV polymerase and has been demonstrated to pro-
uce RNA from both viral and non-viral sources in vitro (Graham
t al., 2011). It can thus be hypothesized that VP1 might stimulate
FNs through synthesis of dsRNA. We  wanted to test this hypothesis
y transfecting TO cells with a mutant VP1 that was defect in RNA
olymerase activity. For this purpose we generated a VP1 sequence
hat was mutated in position 163 since this mutant (VP1S163A) has
een shown neither to be able to guanylylate VP1 nor to be able to
roduce dsRNA (Petit et al., 2000).
VP1S163A was co-transfected into TO-cells together with the
FNa1-promoter construct to see if the mutant VP1 was able to
ctivate the promoter (Fig. 6). Wild-type VP1 was included as a
ositive control. The results showed that the S163A mutation com-
letely abolished VP1s ability to activate the IFNa1 promoter. TheVP1S163A (without polymerase activity), or vector control were included. Results
are presented as mean relative light units (RLU) ± SD (N = 3). Asterisks denote groups
signiﬁcantly different from cells transfected with vector control (p ≤ 0.05).
VP1 and VP1S163A proteins were expressed at comparable levels
when detected with an anti-ﬂag antibody (Fig. S2).
3.6. Antagonistic effect of VP4 is independent of an intact
proteolytic active site
The observation that VP4 was  able to inhibit IPS-1, IRF1 and
IRF3 mediated activation of the IFNa1 promoter, indicated that
VP4 acted on the IRFs or on signaling members involved in IRF-
phosphorylation. An obvious question was if the IFN antagonistic
effect of VP4 was  due to its protease activity (Duncan et al., 1987).
First we studied whether VP4 might degrade IRF1 and IRF3. How-
ever, no degradation of the IRFs could be detected in a Western
blot following co-transfection of VP4 with the IRF1 or IRF3 (data
not shown). We then wanted to test if IFN antagonistic activity of
VP4 was  dependent of its protease activity by creating a protease-
dead mutant of VP4. Since mutations in the site of the lysine general
base K674 have been shown to be even more efﬁcient in abolishing
protease activity than mutating the reactive serine residue (Petit
et al., 2000), this site was  chosen for a single amino acid muta-
tion. This mutation has previously shown to abolish the protease
activity of VP4 with all tested mutations (Petit et al., 2000). The
expressed VP4 and VP4K674A proteins were present in compara-
ble amounts when detected with an anti-ﬂag antibody (Fig. S2).
The constructed VP4K674A was  found to be just as efﬁcient as the
wild type VP4 in inhibition of IPS1-mediated IFNa1 promoter acti-
vation in a co-transfection assay (Fig. 7). This suggests that the IFN
antagonistic property of VP4 is independent of its protease activ-
ity. We  then looked for potential non-covalent binding of VP4 to
the IRFs. However, we  did not observe any binding of IRF1/3 to
VP4 in a co-immunoprecipitation assay (data not shown). As there
are an abundance of proteins and regulators involved in the IRF
branch of the signaling cascade, there are many other potential
targets for inhibition. Unfortunately, far from all of the potential
signaling members have been cloned in Atlantic salmon.
4. Discussion
IPNV replication is strongly inhibited in salmon cells treated bymust therefore be dependent on inhibition of IFN induction during
infection. This is supported by the observation that IPNV infection of
TO cells only resulted in very small changes in the amounts of IFNa
S. Lauksund et al. / Virus Resea
Fig. 7. Effect of the VP4 mutant K674A on activation of the IFNa1 promoter. TO-cells
were co-transfected with a plasmid containing the minimal IFNa1 promoter fused to
a  luciferase gene along with an expression construct for Renilla luciferase as a trans-
fection control. In addition expression constructs for VP4, the mutant VP4K674A
(without protease activity), or a vector control were included. Results are presented
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ms  mean relative light units (RLU) ± SD (N = 3). Asterisks denote groups signiﬁcantly
ifferent from cells transfected with vector control (p ≤ 0.05).
ranscripts (Fig. 1). Moreover, the present work demonstrates that
PNV encodes proteins with powerful IFN antagonistic properties
here all of the proteins encoded by IPNV segment B were able to
nhibit induction of IFNa1 through the RIG-I/MDA5 signaling path-
ay. Overexpression of preVP2, VP3, VP4 and VP5 all inhibited IPS-1
ediated activation of the IFNa1 promoter. While VP4 virtually
bolished IFNa1 promoter activation, preVP2, VP3 and VP5 all dis-
layed a strong albeit not complete inhibition. These viral proteins
re likely to act on signaling factors downstream of IPS-1 since they
ll inhibited activation of the IFNa1 promoter mediated by overex-
ression of IRF1 and IRF3. The mechanisms of inhibition observed
y preVP2, VP3 and VP5 remain to be elucidated. The dsRNA bind-
ng ability of VP3 has previously been proposed as a mechanism for
voiding antiviral host responses (Pedersen et al., 2007). Binding
sRNA is, however, not likely to be the main mechanism of antag-
nism observed in the present studies, as the assays are based on
verexpression of proteins from DNA vectors, and the protein lev-
ls of the transfection control, Renilla luciferase, were not affected
y the presence of VP3. It is thus possible that VP3 has multiple
FN antagonistic properties, a well-known trait in viruses. One of
he most studied viral proteins with multiple functions as an IFN
ntagonist is the non-structural NS1 protein of inﬂuenza A viruses.
n addition to being important for enhancing viral mRNA transla-
ion, NS1 is able to ablate the host innate immune system both by
imiting the induction of IFN by blocking RIG-I activation, and by
irectly inhibiting antiviral proteins such as PKR and OAS/RNaseL.
S1 also inhibits export of mRNA from the nucleus (reviewed in
ale et al., 2008).
Since VP4 possesses protease activity, it was suspected that it
ight cleave members of the RIG-I/MDA5-signaling pathway sim-
lar to several other viral proteases. For instance the picornavirus
Cpro cleaves RIG-I (Barral et al., 2009), and the NS3/4A serine pro-
ease of hepatitis C virus, the NS3/4A protease of GB virus B and
he 3ABC of hepatitis A virus all cleaves IPS-1 (Chen et al., 2007;
i et al., 2005; Yang et al., 2007). However, VP4 mutated to abol-
sh protease activity (K674A), retained its ability to inhibit IPS-1
ediated activation of the IFNa1 promoter. Neither could we  detect
ny degradation products of IRF1 or IRF3 when co-transfected into
ells with VP4. The protease activity of VP4 is thus not likely to be
mportant for its IFNa antagonistic activity in the RIG-I/MDA5 path-
ay downstream of IPS-1. As interactions between VP4 and IRF1
r IRF3 were not observed, VP4 is likely to act on other signaling
embers involved in activation of the IRFs. Potentially VP4 mightrch 196 (2015) 113–121 119
prevent phosphorylation of the IRFs. Other possibilities are that
VP4 might modify the function of the IRFs by promoting or revers-
ing ubiquitination, SUMOylation or ISGylation on the members of
the signaling cascade, similar modiﬁcations have been shown of
other antagonistic viral proteins such as inﬂuenza A virus NS1,
murine hepatitis virus NSP3 and ebolavirus VP35 (Gack et al., 2009;
Kubota et al., 2009; Zheng et al., 2008). It has been shown that the
IFN antagonistic activity of the papain-like protease (PLP) of the
human coronavirus NL63 is independent of its enzymatic activity
(Clementz et al., 2010). The PLP is both a protease and a deubiq-
uitinase, able to process both K-48 and K-63 linked polyubiquitin
chains. Ablating these functions either by mutation or by adding a
protease inhibitor did not inhibit the antagonistic nature of the pro-
tein. Also the protease of the murine hepatitis virus acts as an IFN
antagonist, and even if the antagonistic activity is partly dependent
on the deubiquitinase activity, the protease defective mutants still
retained some antagonistic activity (Zheng et al., 2008). Like these
viral proteases, the IFN antagonistic effect of IPNV VP4 seems to be
independent of an intact catalytic activity.
The birnavirus infectious bursal disease virus (IBDV) is struc-
turally related to IPNV, but causes acute immunosuppressive
disease in birds due to infection of B cells (Mahgoub et al., 2012).
Even if the immunosuppressive nature of IBDV has been well
established, the molecular basis for this mechanism is not fully
understood. It was  recently reported that the VP4 protease of IBDV
is inhibiting IFN expression by interacting with the glucocorticoid-
induced leucine zipper (GILZ) (Li et al., 2013). GILZ has previously
been shown to bind both NF-B and IRF3, inhibiting gene transcrip-
tion directed by these transcription factors (Ogawa et al., 2005;
Reily et al., 2006). Whether IPNV VP4 utilizes a similar mechanism
as the IBDV VP4 in IFN suppression, is a subject for future studies.
A surprising ﬁnding in the present work was the IFN inducible
properties of the viral polymerase VP1. Overexpression of VP1 alone
potently activated the IFNa1 promoter and increased activation
mediated by overexpression of IRF1 and IRF3. Moreover, overex-
pression of VP1 in combination with IRF1 or IRF3 up-regulated IFNa
transcription and increased antiviral activity against IPNV in TO
cells. The antiviral activity from the transfected cells with VP1 in
combination with IRF1 or IRF3 was  due to IFNa since the antiviral
activity of the supernatants could be completely negated by the
addition of IFNa1 antibody. The IFNa inducing properties of VP1
may  be due to synthesis of RNA since it has been demonstrated that
VP1 produces RNA from both viral and non-viral sources in vitro
(Graham et al., 2011). This hypothesis is supported by the fact that
one single amino acid substitution in position 163 abolished the
ability of VP1 to activate IFNa1 promoter activation. The VP1S163A
mutant has been shown neither to be able to guanylylate nor to pro-
duce dsRNA (Xu et al., 2004). Even though the 163 site is not the
actual guanylylation site (Graham et al., 2011), this mutant is deﬁ-
cient in producing dsRNA (Xu et al., 2004). RNA synthesized by VP1
may  be recognized by RIG-I or MDA5 and thus trigger activation of
the IFNa1 promoter. During IPNV infection both viral dsRNA and
non-speciﬁc RNA species formed by VP1 may thus potentially be
recognized by RIG-I/MDA5 risking activation of IFN transcription.
IPNV may  thus have developed multiple IFN antagonizing mecha-
nisms to avoid triggering of IFN synthesis by VP1 since this virus is
highly sensitive to the antiviral activities induced by type I IFNs in
cells. dsRNA could not be detected by a dsRNA antibody after trans-
fecting cells with VP1 (data not shown), but antibody binding might
be dependent of sizes of dsRNA molecules that are larger than the
ones produced by VP1. The concentration of such RNA molecules
is also likely to be low, since VP1 is highly dependent on an IPNV
speciﬁc primer molecule to start synthesis of dsRNA (Dobos, 1995).
In conclusion, Atlantic salmon cells seem to have the ability to
establish an antiviral state by recognizing dsRNA produced by the
IPNV VP1. To overcome this potential barrier of infection, IPNV has
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eveloped multiple mechanisms for inhibition of IFNa induction by
argeting the RIG-I/MDA5 pathway.
onﬂict of interest
There are no actual or potential conﬂicts of interest.
cknowledgements
We thank Professor Jorunn Jørgensen at the University of
romsø, who kindly provided the IPNV vector constructs. This work
as in part supported by the Aquaculture Program of the Research
ouncil of Norway (Grant 185217).
ppendix A. Supplementary data
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.virusres.
014.11.018.
eferences
rpaia, N., Barton, G.M., 2011. Toll-like receptors: key players in antiviral immunity.
Curr. Opin. Virol. 1, 447–454.
arral, P.M., Sarkar, D., Fisher, P.B., Racaniello, V.R., 2009. RIG-I is cleaved during
picornavirus infection. Virology 391, 171–176.
ergan, V., Kileng, O., Sun, B., Robertsen, B., 2010. Regulation and function of inter-
feron regulatory factors of Atlantic salmon. Mol. Immunol. 47, 2005–2014.
ergan, V., Steinsvik, S., Xu, H., Kileng, O., Robertsen, B., 2006. Promoters of type
I  interferon genes from Atlantic salmon contain two main regulatory regions.
FEBS J. 273, 3893–3906.
erke, I.C., Modis, Y., 2012. MDA5 cooperatively forms dimers and ATP-sensitive
ﬁlaments upon binding double-stranded RNA. EMBO J. 31, 1714–1726.
iacchesi, S., LeBerre, M.,  Lamoureux, A., Louise, Y., Lauret, E., Boudinot, P., Bremont,
M.,  2009. Mitochondrial antiviral signaling protein plays a major role in induc-
tion of the ﬁsh innate immune response against RNA and DNA viruses. J. Virol.
83,  7815–7827.
hang, M.,  Collet, B., Nie, P., Lester, K., Campbell, S., Secombes, C.J., Zou, J., 2011.
Expression and functional characterization of the RIG-I-like receptors MDA5
and LGP2 in Rainbow trout (Oncorhynchus mykiss). J. Virol. 85, 8403–8412.
hen, Z., Benureau, Y., Rijnbrand, R., Yi, J., Wang, T., Warter, L., Lanford, R.E., Wein-
man, S.A., Lemon, S.M., Martin, A., Li, K., 2007. GB virus B disrupts RIG-I signaling
by  NS3/4A-mediated cleavage of the adaptor protein MAVS. J. Virol. 81, 964–976.
hin, K.C., Cresswell, P., 2001. Viperin (cig5), an IFN-inducible antiviral protein
directly induced by human cytomegalovirus. Proc. Natl. Acad. Sci. U. S. A. 98,
15125–15130.
hristie, K.E., Havarstein, L.S., Djupvik, H.O., Ness, S., Endresen, C., 1988. Character-
ization of a new serotype of infectious pancreatic necrosis virus isolated from
Atlantic salmon. Arch. Virol. 103, 167–177.
lementz, M.A., Chen, Z., Banach, B.S., Wang, Y., Sun, L., Ratia, K., Baez-Santos, Y.M.,
Wang, J., Takayama, J., Ghosh, A.K., Li, K., Mesecar, A.D., Baker, S.C., 2010. Deu-
biquitinating and interferon antagonism activities of coronavirus papain-like
proteases. J. Virol. 84, 4619–4629.
oulibaly, F., Chevalier, C., Gutsche, I., Pous, J., Navaza, J., Bressanelli, S., Delmas, B.,
Rey, F.A., 2005. The birnavirus crystal structure reveals structural relationships
among icosahedral viruses. Cell 120, 761–772.
obos, P., 1976. Size and structure of the genome of infectious pancreatic necrosis
virus. Nucleic Acids Res. 3, 1903–1924.
obos, P., 1995. Protein-primed RNA synthesis in vitro by the virion-associated RNA
polymerase of infectious pancreatic necrosis virus. Virology 208, 19–25.
uncan, R., Nagy, E., Krell, P.J., Dobos, P., 1987. Synthesis of the infectious pancre-
atic necrosis virus polyprotein, detection of a virus-encoded protease, and ﬁne
structure mapping of genome segment A coding regions. J. Virol. 61, 3655–3664.
eng, H., Liu, H., Kong, R., Wang, L., Wang, Y., Hu, W.,  Guo, Q., 2011. Expression proﬁles
of  carp IRF-3/-7 correlate with the up-regulation of RIG-I/MAVS/TRAF3/TBK1,
four pivotal molecules in RIG-I signaling pathway. Fish Shellﬁsh Immunol. 30,
1159–1169.
ack, M.U., Albrecht, R.A., Urano, T., Inn, K.S., Huang, I.C., Carnero, E., Farzan, M.,
Inoue, S., Jung, J.U., Garcia-Sastre, A., 2009. Inﬂuenza A virus NS1 targets the
ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I.
Cell  Host Microbe 5, 439–449.
raham, S.C., Sarin, L.P., Bahar, M.W.,  Myers, R.A., Stuart, D.I., Bamford, D.H., Grimes,
J.M., 2011. The N-terminus of the RNA polymerase from infectious pancre-
atic necrosis virus is the determinant of genome attachment. PLoS Pathog. 7,
e1002085.
ale, B.G., Randall, R.E., Ortin, J., Jackson, D., 2008. The multifunctional NS1 protein
of  inﬂuenza A viruses. J. Gen. Virol. 89, 2359–2376.rch 196 (2015) 113–121
Heppell, J., Tarrab, E., Berthiaume, L., Lecomte, J., Arella, M.,  1995. Characterization
of  the small open reading frame on genome segment A of infectious pancreatic
necrosis virus. J. Gen. Virol. 76, 2091–2096.
Hill, B.J., Way, K., 1995. Serological classiﬁcation of infectious pancreatic necro-
sis  (IPN) virus and other aquatic birnaviruses. Ann. Rev. Fish Dis. 5,
55–77.
Holland, J.W., Bird, S., Williamson, B., Woudstra, C., Mustafa, A., Wang, T., Zou, J.,
Blaney, S.C., Collet, B., Secombes, C.J., 2008. Molecular characterization of IRF3
and  IRF7 in rainbow trout, Oncorhynchus mykiss: functional analysis and trans-
criptional modulation. Mol. Immunol. 46, 269–285.
Jarp, J., Gjevre, A.G., Olsen, A.B., Bruheim, T., 1995. Risk-factors for furunculosis, infec-
tious pancreatic necrosis and mortality in post-smolt of Atlantic salmon, Salmo
salar L. J. Fish Dis. 18, 67–78.
Jiang, F., Ramanathan, A., Miller, M.T., Tang, G.Q., Gale Jr., M., Patel, S.S., Marcot-
rigiano, J., 2011. Structural basis of RNA recognition and activation by innate
immune receptor RIG-I. Nature 479, 423–427.
Kubota, T., Matsuoka, M., Chang, T.H., Bray, M.,  Jones, S., Tashiro, M.,  Kato, A., Ozato,
K., 2009. Ebolavirus VP35 interacts with the cytoplasmic dynein light chain 8. J.
Virol. 83, 6952–6956.
Lauksund, S., Svingerud, T., Bergan, V., Robertsen, B., 2009. Atlantic salmon IPS-
1  mediates induction of IFNa1 and activation of NF-kappaB and localizes to
mitochondria. Dev. Comp. Immunol. 33, 1196–1204.
Li, X.D., Sun, L., Seth, R.B., Pineda, G., Chen, Z.J., 2005. Hepatitis C virus protease
NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria
to  evade innate immunity. Proc. Natl. Acad. Sci. U. S. A. 102, 17717–17722.
Li, Z., Wang, Y., Li, X., Li, X., Cao, H., Zheng, S.J., 2013. Critical roles of glucocorticoid-
induced leucine zipper in infectious bursal disease virus (IBDV)-induced
suppression of type I interferon expression and enhancement of IBDV growth
in host cells via interaction with VP4. J. Virol. 87, 1221–1231.
Liu, S.Y., Sanchez, D.J., Cheng, G., 2011. New developments in the induc-
tion and antiviral effectors of type I interferon. Curr. Opin. Immunol. 23,
57–64.
Mahgoub, H.A., Bailey, M.,  Kaiser, P., 2012. An overview of infectious bursal disease.
Arch. Virol. 157, 2047–2057.
Ogawa, S., Lozach, J., Benner, C., Pascual, G., Tangirala, R.K., Westin, S., Hoffmann, A.,
Subramaniam, S., David, M.,  Rosenfeld, M.G., Glass, C.K., 2005. Molecular deter-
minants of crosstalk between nuclear receptors and toll-like receptors. Cell 122,
707–721.
Ohtani, M., Hikima, J., Hwang, S.D., Morita, T., Suzuki, Y., Kato, G.,  Kondo, H., Hirono,
I.,  Jung, T.S., Aoki, T., 2012. Transcriptional regulation of type I interferon gene
expression by interferon regulatory factor-3 in Japanese ﬂounder, Paralichthys
olivaceus. Dev. Comp. Immunol. 36, 697–706.
Ohtani, M.,  Hikima, J., Kondo, H., Hirono, I., Jung, T.S., Aoki, T., 2011. Characterization
and  antiviral function of a cytosolic sensor gene, MDA5, in Japanese ﬂounder,
Paralichthys olivaceus. Dev. Comp. Immunol. 35, 554–562.
Pedersen, T., Skjesol, A., Jorgensen, J.B., 2007. VP3, a structural protein of infectious
pancreatic necrosis virus, interacts with RNA-dependent RNA polymerase VP1
and with double-stranded RNA. J. Virol. 81, 6652–6663.
Petit, S., Lejal, N., Huet, J.C., Delmas, B., 2000. Active residues and viral substrate
cleavage sites of the protease of the birnavirus infectious pancreatic necrosis
virus. J. Virol. 74, 2057–2066.
Pfafﬂ, M.W.,  Horgan, G.W., Dempﬂe, L., 2002. Relative expression software tool
(REST) for group-wise comparison and statistical analysis of relative expression
results in real-time PCR. Nucleic Acids Res. 30, e36.
Pous, J., Chevalier, C., Ouldali, M.,  Navaza, J., Delmas, B., Lepault, J., 2005. Structure of
birnavirus-like particles determined by combined electron cryomicroscopy and
X-ray crystallography. J. Gen. Virol. 86, 2339–2346.
Randall, R.E., Goodbourn, S., 2008. Interferons and viruses: an interplay between
induction, signalling, antiviral responses and virus countermeasures. J. Gen.
Virol. 89, 1–47.
Reed, L.J., Muench, H., 1938. A simple method of estimating ﬁfty percent endpoints.
Am.  J. Hyg. 27, 493–497.
Reily, M.M.,  Pantoja, C., Hu, X., Chinenov, Y., Rogatsky, I., 2006. The GRIP1:IRF3 inter-
action as a target for glucocorticoid receptor-mediated immunosuppression.
EMBO J. 25, 108–117.
Robertsen, B., Bergan, V., Rokenes, T., Larsen, R., Albuquerque, A., 2003. Atlantic
salmon interferon genes: cloning, sequence analysis, expression, and biological
activity. J. Interferon Cytokine Res. 23, 601–612.
Rokenes, T.P., Larsen, R., Robertsen, B., 2007. Atlantic salmon ISG15: expression and
conjugation to cellular proteins in response to interferon, double-stranded RNA
and virus infections. Mol. Immunol. 44, 950–959.
Samuel, C.E., 2001. Antiviral actions of interferons. Clin. Microbiol. Rev. 14, 778–809,
table of contents.
Santi, N., Sandtro, A., Sindre, H., Song, H., Hong, J.R., Thu, B., Wu,  J.L., Vakharia, V.N.,
Evensen, O., 2005. Infectious pancreatic necrosis virus induces apoptosis in vitro
and in vivo independent of VP5 expression. Virology 342, 13–25.
Simora, R.M., Ohtani, M.,  Hikima, J., Kondo, H., Hirono, I., Jung, T.S., Aoki, T., 2010.
Molecular cloning and antiviral activity of IFN-beta promoter stimulator-1 (IPS-
1)  gene in Japanese ﬂounder, Paralichthys olivaceus. Fish Shellﬁsh Immunol. 29,
979–986.
Skjesol, A., Skjaeveland, I., Elnaes, M.,  Timmerhaus, G., Fredriksen, B.N., Jorgensen,
S.M., Krasnov, A., Jorgensen, J.B., 2011. IPNV with high and low virulence: host
immune responses and viral mutations during infection. Virol J. 8, 396.
Skjesol, A., Aamo, T., Hegseth, M.N., Robertsen, B., Jorgensen, J.B., 2009. The interplay
between infectious pancreatic necrosis virus (IPNV) and the IFN system: IFN
signaling is inhibited by IPNV infection. Virus Res. 143, 53–60.
Resea
S
S
S
S
SS. Lauksund et al. / Virus 
mail, D.A., Bruno, D.W., Dear, G., Mcfarlane, L.A., Ross, K., 1992. Infectious pan-
creatic necrosis (IPN) virus Sp serotype in farmed Atlantic salmon Salmo salar
L.,  post-smolts associated with mortality and clinical disease. J. Fish Dis. 15,
77–83.
u, J., Huang, T., Dong, J., Heng, J., Zhang, R., Peng, L., 2010. Molecular cloning and
immune responsive expression of MDA5 gene, a pivotal member of the RLR
gene family from grass carp Ctenopharyngodon idella. Fish Shellﬁsh Immunol.
28, 712–718.
un, B., Robertsen, B., Wang, Z., Liu, B., 2009. Identiﬁcation of an Atlantic salmon IFN
multigene cluster encoding three IFN subtypes with very different expression
properties. Dev. Comp. Immunol. 33, 547–558.
un, F., Zhang, Y.B., Liu, T.K., Shi, J., Wang, B., Gui, J.F., 2011. Fish MITA serves as
a  mediator for distinct ﬁsh IFN gene activation dependent on IRF3 or IRF7. J.
Immunol. 187, 2531–2539.
vingerud, T., Solstad, T., Sun, B., Nyrud, M.L., Kileng, O., Greiner-Tollersrud, L.,
Robertsen, B., 2012. Atlantic salmon type I IFN subtypes show differences in
antiviral activity and cell-dependent expression: evidence for high IFNb/IFNc-
producing cells in ﬁsh lymphoid tissues. J. Immunol. 189, 5912–5923.rch 196 (2015) 113–121 121
Takeuchi, O., Akira, S., 2007. Recognition of viruses by innate immunity. Immunol.
Rev. 220, 214–224.
van den Broek, M.F., Muller, U., Huang, S., Zinkernagel, R.M., Aguet, M.,  1995. Immune
defence in mice lacking type I and/or type II interferon receptors. Immunol. Rev.
148, 5–18.
Wergeland, H.I., Jakobsen, R.A., 2001. A salmonid cell line (TO) for production of
infectious salmon anaemia virus (ISAV). Dis. Aquat. Organ. 44, 183–190.
Xu, H.T., Si, W.D., Dobos, P., 2004. Mapping the site of guanylylation on VP1, the
protein primer for infectious pancreatic necrosis virus RNA synthesis. Virology
322, 199–210.
Yang, Y., Liang, Y., Qu, L., Chen, Z., Yi, M.,  Li, K., Lemon, S.M., 2007. Disruption of innate
immunity due to mitochondrial targeting of a picornaviral protease precursor.
Proc. Natl. Acad. Sci. U. S. A. 104, 7253–7258.Zheng, D., Chen, G., Guo, B., Cheng, G., Tang, H., 2008. PLP2, a potent deubiqui-
tinase from murine hepatitis virus, strongly inhibits cellular type I interferon
production. Cell Res. 18, 1105–1113.
Zou, J., Chang, M.,  Nie, P., Secombes, C.J., 2009. Origin and evolution of the RIG-I like
RNA helicase gene family. BMC Evol. Biol. 9, 85.
